Sex differences and disparities in cardiovascular outcomes of COVID-19.


Journal

Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427

Informations de publication

Date de publication:
22 05 2023
Historique:
received: 12 05 2022
revised: 24 08 2022
accepted: 20 11 2022
medline: 24 5 2023
pubmed: 19 1 2023
entrez: 18 1 2023
Statut: ppublish

Résumé

Previous analyses on sex differences in case fatality rates at population-level data had limited adjustment for key patient clinical characteristics thought to be associated with coronavirus disease 2019 (COVID-19) outcomes. We aimed to estimate the risk of specific organ dysfunctions and mortality in women and men. This retrospective cross-sectional study included 17 hospitals within 5 European countries participating in the International Survey of Acute Coronavirus Syndromes COVID-19 (NCT05188612). Participants were individuals hospitalized with positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from March 2020 to February 2022. Risk-adjusted ratios (RRs) of in-hospital mortality, acute respiratory failure (ARF), acute heart failure (AHF), and acute kidney injury (AKI) were calculated for women vs. men. Estimates were evaluated by inverse probability weighting and logistic regression models. The overall care cohort included 4499 patients with COVID-19-associated hospitalizations. Of these, 1524 (33.9%) were admitted to intensive care unit (ICU), and 1117 (24.8%) died during hospitalization. Compared with men, women were less likely to be admitted to ICU [RR: 0.80; 95% confidence interval (CI): 0.71-0.91]. In general wards (GWs) and ICU cohorts, the adjusted women-to-men RRs for in-hospital mortality were of 1.13 (95% CI: 0.90-1.42) and 0.86 (95% CI: 0.70-1.05; pinteraction = 0.04). Development of AHF, AKI, and ARF was associated with increased mortality risk (odds ratios: 2.27, 95% CI: 1.73-2.98; 3.85, 95% CI: 3.21-4.63; and 3.95, 95% CI: 3.04-5.14, respectively). The adjusted RRs for AKI and ARF were comparable among women and men regardless of intensity of care. In contrast, female sex was associated with higher odds for AHF in GW, but not in ICU (RRs: 1.25; 95% CI: 0.94-1.67 vs. 0.83; 95% CI: 0.59-1.16, pinteraction = 0.04). Women in GW were at increased risk of AHF and in-hospital mortality for COVID-19 compared with men. For patients receiving ICU care, fatal complications including AHF and mortality appeared to be independent of sex. Equitable access to COVID-19 ICU care is needed to minimize the unfavourable outcome of women presenting with COVID-19-related complications.

Identifiants

pubmed: 36651866
pii: 6991257
doi: 10.1093/cvr/cvad011
doi:

Banques de données

ClinicalTrials.gov
['NCT05188612']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1190-1201

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Déclaration de conflit d'intérêts

Conflicts of interests: The authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Raffaele Bugiardini (R)

Department of Medical and Surgical Sciences, University of Bologna, Padiglione 11, Via Massarenti 9, 40138 Bologna, Italy.

Stefano Nava (S)

Department of Medical and Surgical Sciences, University of Bologna, Padiglione 11, Via Massarenti 9, 40138 Bologna, Italy.
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Respiratory and Critical Care Unit, Bologna, Italy.

Gaetano Caramori (G)

Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF), University of Messina, Messina, Italy.

Jinsung Yoon (J)

Google Cloud AI, Sunnyvale, CA, USA.

Lina Badimon (L)

Cardiovascular Research Program ICCC, IR-IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, CiberCV-Institute Carlos III, Barcelona, Spain.

Maria Bergami (M)

Department of Medical and Surgical Sciences, University of Bologna, Padiglione 11, Via Massarenti 9, 40138 Bologna, Italy.

Edina Cenko (E)

Department of Medical and Surgical Sciences, University of Bologna, Padiglione 11, Via Massarenti 9, 40138 Bologna, Italy.

Antonio David (A)

Department of Human Pathology of the Adult and Evolutive Age "Gaetano Barresi", Division of Anesthesia and Critical Care, University of Messina, Messina, Italy.

Ilir Demiri (I)

University Clinic of Infectious Diseases, University 'Ss. Cyril and Methodius', Skopje, North Macedonia.

Maria Dorobantu (M)

Emergency Clinical Hospital of Bucharest, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania.

Oana Fronea (O)

Emergency Clinical Hospital of Bucharest, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania.

Radmilo Jankovic (R)

Clinic for Anesthesiology and Intensive Therapy, University Clinical Center Nis, School of Medicine, University of Nis, Nis, Serbia.

Sasko Kedev (S)

University Clinic for Cardiology, 1000 Skopje, Republic of North Macedonia.
Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia.

Nebojsa Ladjevic (N)

Faculty of Medicine, University of Belgrade, University Clinical Centre of Serbia, Belgrade, Serbia.

Ratko Lasica (R)

Clinical Center of Serbia, University of Belgrade, Belgrade, Serbia.

Goran Loncar (G)

Institute for Cardiovascular Diseases Dedinje, Belgrade, Serbia.

Giuseppe Mancuso (G)

Medical Microbiology, Department of Human Pathology, University of Messina, Messina, Italy.

Guiomar Mendieta (G)

Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

Davor Miličić (D)

Department for Cardiovascular Diseases, University Hospital Center Zagreb, University of Zagreb, Zagreb, Croatia.

Petra Mjehović (P)

Department for Cardiovascular Diseases, University Hospital Center Zagreb, University of Zagreb, Zagreb, Croatia.

Marijan Pašalić (M)

Department for Cardiovascular Diseases, University Hospital Center Zagreb, University of Zagreb, Zagreb, Croatia.

Milovan Petrović (M)

Institute of Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Faculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.

Lidija Poposka (L)

University Clinic for Cardiology, 1000 Skopje, Republic of North Macedonia.
Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia.

Marialuisa Scarpone (M)

Department of Medical and Surgical Sciences, University of Bologna, Padiglione 11, Via Massarenti 9, 40138 Bologna, Italy.

Milena Stefanovic (M)

University Clinic of Infectious Diseases, University 'Ss. Cyril and Methodius', Skopje, North Macedonia.

Mihaela van der Schaar (M)

Department of Electrical and Computer Engineering, University of California, Los Angeles, CA, USA.
Cambridge Centre for Artificial Intelligence in Medicine, Department of Applied Mathematics and Theoretical Physics and Department of Population Health, University of Cambridge, Cambridge, UK.

Zorana Vasiljevic (Z)

Medical Faculty, University of Belgrade, Belgrade, Serbia.

Marija Vavlukis (M)

University Clinic for Cardiology, 1000 Skopje, Republic of North Macedonia.
Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 1000 Skopje, Republic of North Macedonia.

Maria Laura Vega Pittao (ML)

Department of Medical and Surgical Sciences, University of Bologna, Padiglione 11, Via Massarenti 9, 40138 Bologna, Italy.
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Respiratory and Critical Care Unit, Bologna, Italy.

Vladan Vukomanovic (V)

Clinical Hospital Center Dragiša Mišković, Belgrade, Serbia.

Marija Zdravkovic (M)

Faculty of Medicine, University of Belgrade, Clinical Hospital Center Bezanijska kosa, Belgrade, Serbia.

Olivia Manfrini (O)

Department of Medical and Surgical Sciences, University of Bologna, Padiglione 11, Via Massarenti 9, 40138 Bologna, Italy.
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Sant'Orsola Hospital, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH